Dublin, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022" report to their offering.
The report throws a light over the clinical relevance of personalized forms and identifies the risk and commercial aspects along with the potential outcome for the success of personalized cancer vaccines in the upcoming future directions.
During the last decade, great efforts have been made to develop immunotherapeutic approaches for the treatment of malignant diseases as alternatives to traditional chemotherapy and radiotherapy. A quintessential goal of immunotherapy in cancer is treatment with vaccines that elicit potent anti-tumor immune responses without side effects. The upsurge of immunotherapeutics in oncology is remarkable and the trail towards getting personalized is in future trends. With the development of the pharmacogenomics and genome mapping resolutions towards human genome are making personalized vaccines to be more efficacious. The platform for the personalization of vaccines had been built by the human genome project.
Geographically, the acceptance of personalization is greater in the western world as both the new and old vaccine approaches towards the cancer are transforming the landscape of the major markets of western world including US, Western Europe and Japan. In contrary the concept is less influential in the low and middle income countries. Nevertheless, in the upcoming time the improvement will surely administer the challenges of cost and distribution which will aid the personalization in the Asia-Pacific regions.
Oncological segment has gained a great momentum with the advent of modern technologies and the better equipped sequencing methodology. Over the past years, there has been gradual paradigm shift from traditional medicine and accelerated acceptance towards the precision medication. Physicians are opting for the personalization of the medicines according to the genomic makeup of the patient.
The personalized cancer vaccine will be beneficial to the patients as the treatment will be generated personally for the individual which will target the fundamental driver of their disease while also potentially avoiding toxicity. In terms of cost and savings the payers found personalization to be attractive as mechanism to control usage of expensive drugs and can avoid the wasteful expenditure on treatments that are ineffective.
In contrary, it also provides better future opportunities for pharmaceuticals too although there are several challenges and unmet needs which has to be defined first. Many pharmaceutical companies have calculated the improvised vision for the right drug, right patient and the right time. This concept saves the resources, time and provides ample opportunities to achieve substantial medications for the investors.
The future potential of personalized cancer vaccines for the detection, management and preventing diseases is primarily dependent on the ongoing genomic projects, merging translational medicines and advances in personal genetic testing and developing targeted therapy. Such innovative therapies are also welcomed by the physicians as these approaches minimize the trial and error diagnosis and treatment.
The personalized cancer vaccine will be beneficial to the patients as the treatment will be generated personally for the individual which will target the fundamental driver of their disease while also potentially avoiding toxicity. In terms of cost and savings the payers found personalization to be attractive as mechanism to control usage of expensive drugs and can avoid the wasteful expenditure on treatments that are ineffective.
Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022 Report Highlights:
- Introduction to Personalized Cancer Vaccines
- Identification of Tumor Neoantigens
- Development & Mechanism of Personalized Vaccines
- Categories of Personalized Cancer Vaccines
- Biomarkers for Personalized Vaccines
- Personalized Vaccines for Multiple Cancers
- Current & Future Market Outlook of Personalized Cancer Vaccines
Companies Mentioned
- Advaxis Inc.
- Avax Technologies
- BioNtech
- Celldex
- Genentech Inc.
- Genocea
- ISA Pharmaceuticals
- Merck & Co.
- Moderna
- Neon Therapeutics
For more information about this report visit http://www.researchandmarkets.com/research/x77k45/personalized